Patents Assigned to Aldagen, Inc.
-
Patent number: 8986744Abstract: The present invention relates to populations of stem cells, methods for isolating these stem cell populations, and methods repairing, regenerating, and reconstituting tissues using the these stem cell populations. The invention additionally relates to methods of screening agents that promote growth, engraftment, or differentiation of stem cells.Type: GrantFiled: December 13, 2010Date of Patent: March 24, 2015Assignee: Aldagen, Inc.Inventors: Tracy Gentry, Sandra J. Foster, Andrew E. Balber
-
Publication number: 20110189211Abstract: The present invention relates to populations of stem cells, methods for isolating these stem cell populations, and methods repairing, regenerating, and reconstituting tissues using the these stem cell populations. The invention additionally relates to methods of screening agents that promote growth, engraftment, or differentiation of stem cells.Type: ApplicationFiled: December 13, 2010Publication date: August 4, 2011Applicant: Aldagen, Inc.Inventors: Tracy Gentry, Sandra J. Foster, Andrew E. Balber
-
Patent number: 7863043Abstract: Populations of stem cells and methods for their isolation and use are provided. These stem cell populations comprise aldehyde dehydrogenase positive (ALDHbr) cells isolated from bone marrow, and ALDHbr CD105+ cells derived from any stem cell source. These populations may also comprise cells expressing such surface markers as CD34, CD38, CD41, CD45, CD105, CD133, CD135, CD117, and HLA-DR, and/or are substantially free from such cell surface markers as CD3, CD7, CD 10, CD 13, CD 14, C1319, CD33, CD35, CD56, CD 127, CD 138, and glycophorin A. The population may also comprise cells expressing CD90. The stem cell populations of the invention are isolated from a stem cell source such as bone marrow, peripheral blood, umbilical cord blood, and fetal liver. Methods of the invention comprise isolating and purifying stem cell populations from stem cell sources, and methods of using these cells to reconstitute, repair, and regenerate tissues.Type: GrantFiled: May 4, 2004Date of Patent: January 4, 2011Assignee: Aldagen, Inc.Inventors: Tracy Gentry, Sandra J. Foster, Andrew E. Balber
-
Publication number: 20100129329Abstract: The present invention relates to methods repairing, regenerating, and reconstituting tissues by transplanting at least two stem cell populations, wherein the first and the second population of stem cells are introduced into a subject separated by a time interval of about 2 to about 24 hours. The first population comprises stem cells derived from umbilical cord. The second population comprises ALDHbr cells. These ALDHbr cells can be administered to a patient immediately after isolation or can be primed in culture using a combination of cytokines for about 2 to about 7 days prior to transplantation. The methods of the invention are useful in accelerating time to neutrophil and/or platelet engraftment and immune reconstitution following myeloablative therapy.Type: ApplicationFiled: November 8, 2007Publication date: May 27, 2010Applicants: ALDAGEN, INC., DUKE UNIVERSITYInventors: N. Rebecca Haley, Joanne Kurtzberg
-
Publication number: 20100111905Abstract: The present invention relates to methods repairing, regenerating, and reconstituting tissues by transplanting at least two stem cell populations, wherein the first and the second population of stem cells are introduced into a subject separated by a time interval of about 2 to about 24 hours. The stem cells can be derived from umbilical cord, mobilized peripheral blood, or bone marrow. The cells of at least the second population may be enriched for adult stem and progenitor cells. The methods of the invention are useful in accelerating hematopoeitic recovery in subjects following myeloablation or chemotherapy.Type: ApplicationFiled: November 8, 2007Publication date: May 6, 2010Applicant: ALDAGEN,INC.Inventor: Andrew E. Balber
-
Publication number: 20080241171Abstract: Populations of stem cells and methods for their isolation and use are provided. These stem cell populations comprise aldehyde dehydrogenase positive (ALDHbr) cells isolated from bone marrow, and ALDHbr CD105+ cells derived from any stem cell source. These populations may also comprise cells expressing such surface markers as CD34, CD38, CD41, CD45, CD105, CD133, CD135, CD117, and HLA-DR, and/or are substantially free from such cell surface markers as CD3, CD7, CD 10, CD 13, CD 14, C1319, CD33, CD35, CD56, CD 127, CD 138, and glycophorin A. The population may also comprise cells expressing CD90. The stem cell populations of the invention are isolated from a stem cell source such as bone marrow, peripheral blood, umbilical cord blood, and fetal liver. Methods of the invention comprise isolating and purifying stem cell populations from stem cell sources, and methods of using these cells to reconstitute, repair, and regenerate tissues.Type: ApplicationFiled: May 4, 2004Publication date: October 2, 2008Applicant: Aldagen , Inc.Inventors: Tracy Gentry, Sandra J. Foster, Andrew E. Balber